This CPB has been revised to: (i) restructure the medical necessity criteria for Eliglustat (Cerdelga),Imiglucerase (Cerezyme), Taliglucerase alfa (Elelyso), and Velaglucerase alfa (VPRIV), and Miglustat (Zavesca); and (ii) remove the criteria “and the member is experiencing neurological symptoms” from Type 3 Gaucher disease. The title of this CPB has been changed to "Lysosomal Storage Disorder Treatments."